<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Biotechnol</journal-id><journal-id journal-id-type="publisher-id">JBB</journal-id><journal-title>Journal of Biomedicine and Biotechnology</journal-title><issn pub-type="ppub">1110-7243</issn><issn pub-type="epub">1110-7251</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17047304</article-id><article-id pub-id-type="pmc">1559914</article-id><article-id pub-id-type="doi">10.1155/JBB/2006/31825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Dysregulation of Protein Phosphorylation/Dephosphorylation
in Alzheimer's Disease: A Therapeutic Target</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Cheng-Xin</given-names></name><xref rid="a" ref-type="aff"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fei</given-names></name><xref rid="a" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Grundke-Iqbal</surname><given-names>Inge</given-names></name><xref rid="a" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Khalid</given-names></name><xref rid="a" ref-type="aff"/></contrib></contrib-group><aff id="a">Department of Neurochemistry, New York State
Institute for Basic Research in Developmental Disabilities, 1050
Forest Hill Road, Staten Island, NY 10314-6399, USA</aff><author-notes><corresp id="cor1">*Cheng-Xin Gong: <email>cxgong@ultinet.net</email></corresp></author-notes><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>21</day><month>3</month><year>2006</year></pub-date><volume>2006</volume><elocation-id>31825</elocation-id><history><date date-type="received"><day>8</day><month>11</month><year>2005</year></date><date date-type="rev-recd"><day>12</day><month>12</month><year>2005</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Cheng-Xin Gong et al.</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Studies during the last two decades have provided new insights
into the molecular mechanism of Alzheimer's disease (AD). One of
the milestone findings in AD research was the demonstration that
neurofibrillary degeneration characterized by tau pathology is
central to the pathogenesis of AD and other tauopathies and that
abnormal hyperphosphorylation of tau is pivotal to neurofibrillary
degeneration. This article reviews the recent research advances in
tau pathology and the underlying dysregulation of the protein
phosphorylation/dephosphorylation system. An updated model of the
mechanism of neurofibrillary degeneration is also presented, and a
promising therapeutic target to treat AD by correcting
dysregulation of protein phosphorylation/dephosphorylation is
discussed.</p></abstract></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>Although Alzheimer's disease (AD) and its main brain histopathology, that is, senile plaques and
neurofibrillary tangles (NFTs), were described a century ago,
significant research advances in the disease began only a few
decades ago. The discoveries of the major protein components of
senile plaques as amyloid &#x003b2;-peptide [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>] and of NFTs
as abnormally hyperphosphorylated tau [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>] in the 1980s
initiated a new era of AD research. Since then, much research has
focused on the molecular mechanisms of initiation and formation of
the senile plaques and NFTs and their roles in the pathogenesis of
AD. Evidence accumulated in the last two decades indicates that
malprocessing of both tau and &#x003b2;-amyloid precursor protein,
which produces &#x003b2;-peptide, is pivotal, if not central, to the
molecular mechanism of AD. The severity of dementia symptoms in AD
strongly correlates to the number of NFTs, but not of senile
plaques, in AD brains [<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>], suggesting that tau
pathology might be associated with the disease mechanism more
directly. Abnormal hyperphosphorylation of tau and its deposits in
the brain is also seen in several other neurodegenerative diseases
that are collectively named tauopathies (for review, see
[<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]). The discovery of tau mutations that cause
hereditary  frontotemporal dementia and Parkinsonism linked to
chromosome 17  (FTDP-17) [<xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>] further indicates that
tau abnormality alone is sufficient to produce dementia.
Therefore, for developing rational therapeutic
treatment of AD, it is essential to understand the molecular
mechanism by which tau abnormalities lead to neurofibrillary
degeneration.</p><p>Because tau aggregated in the brain of AD and all other
tauopathies is always abnormally hyperphosphorylated, numerous
studies have focused on the roles of the abnormal
hyperphosphorylation and the mechanism leading to tau
hyperphosphorylation. Recent studies demonstrate that it is the
abnormal hyperphosphorylation that makes tau lose its normal
function to stimulate microtubule assembly, gain toxic activity,
and aggregate into NFTs [<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>]. In
addition to tau, several other brain proteins such as
neurofilaments, microtubule-associated protein (MAP) 1&#x02009;B,
&#x003b2;-tubulin, and &#x003b2;-catenin are also found to be
hyperphosphorylated [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>], suggesting that the
protein phosphorylation/dephosphorylation system might be
dysregulated in AD brain. This article attempts to review the
recent advances in this respect. Because abnormally
hyperphosphorylated tau is pivotal to AD and has been extensively
studied, this review focuses on tau hyperphosphorylation.
Prevention and reversal of abnormal hyperphosphorylation of tau as
a potential promising therapeutic strategy is also discussed.</p></sec><sec sec-type="tau protein"><title>TAU PROTEIN</title><p>Tau was first discovered by Weingarten et al [<xref ref-type="bibr" rid="B28">28</xref>] as a microtubule-associated protein that stimulates
microtubule assembly. There was not much research
interest in tau protein until a decade later, when it was found to
make up the paired helical filaments (PHFs) that form NFTs in AD
brain [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B29">29</xref>]. Human tau gene was found on the long arm of
chromosome 17 (position 17q21) and was found to contain 16 exons
[<xref ref-type="bibr" rid="B30">30</xref>]. This single tau gene encodes six tau isoforms in adult
human brain as a result of alternative splicing of its mRNA
[<xref ref-type="bibr" rid="B31">31</xref>]. The six isoforms of tau differ from each other by the
presence or absence of one or two inserts (29 or 58 amino acids)
in the <italic>N</italic>-terminal part and by the presence of either three or
four repeats in the <italic>C</italic>-terminal half. The <italic>N</italic>-terminal inserts
are highly acidic. The repeats in the <italic>C</italic>-terminal half of tau are
the domains that bind to microtubules [<xref ref-type="bibr" rid="B32">32</xref>&#x02013;<xref ref-type="bibr" rid="B34">34</xref>]. The region
upstream of the microtubule-binding domains contains many proline
residues and, hence, is called the proline-rich region.</p><p>The best-known biological functions of tau are to stimulate
microtubule assembly and to stabilize microtubule structure. Tau
binds to microtubules via its microtubule-binding domains located
at the <italic>C</italic>-terminal half of the molecule [<xref ref-type="bibr" rid="B32">32</xref>&#x02013;<xref ref-type="bibr" rid="B34">34</xref>]. The
<italic>N</italic>-terminal part projects from the microtubule surface, where it
may interact with other cytoskeletal elements and the plasma
membrane [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Each of the six tau isoforms possibly has
its particular physiological roles and differential biological
activities, because they are differentially expressed during
development and have different activities to stimulate microtubule
assembly [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>]. Only the shortest isoform of tau is
expressed in fetal brain, whereas all six isoforms are seen in
adult brain [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>]. In addition to stimulating microtubule
assembly, several studies have suggested that tau may have other
physiological functions. It appears to interfere with binding of
kinesin and kinesin-like motors to microtubules, leading to a
preferential inhibition of plus-end-directed axonal transport
[<xref ref-type="bibr" rid="B41">41</xref>]. Overexpression of tau inhibits kinesin-dependent
trafficking of vesicles, mitochondria, and endoplasmic reticulum
[<xref ref-type="bibr" rid="B42">42</xref>]. This may explain the symptoms of amyotrophic lateral
sclerosis with neurofilament accumulation in motor neurons of
several transgenic models of tau overexpression
[<xref ref-type="bibr" rid="B43">43</xref>&#x02013;<xref ref-type="bibr" rid="B46">46</xref>]. Tau has been found to interact with
mitochondria [<xref ref-type="bibr" rid="B47">47</xref>], plasma membrane [<xref ref-type="bibr" rid="B36">36</xref>], and nucleic
acids [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>], suggesting that it may act as a mediator
between microtubules and these organelles. Tau also appears to
interact with src-family nonreceptor tyrosine kinases such as fyn
[<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>] and phospholipase <italic>C</italic>-&#x003b3; [<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>] via
its proline-rich region. These data suggest that tau may also play
a role in the signal transduction pathways involving src-family
tyrosine kinases and phospholipase <italic>C</italic>-&#x003b3;. However, the physiological significance of these interactions remains to be
elucidated.</p><p>As early as 1977, tau was found to be a phosphoprotein [<xref ref-type="bibr" rid="B54">54</xref>].
In 1984, it was demonstrated that phosphorylation of tau
negatively regulates its activity in promoting microtubule
assembly [<xref ref-type="bibr" rid="B55">55</xref>]. Because tau is abnormally hyperphosphorylated
in AD and other tauopathies, tau phosphorylation has been studied
extensively. Normal brain tau contains 2 or 3 moles of phosphates
per mole of tau [<xref ref-type="bibr" rid="B56">56</xref>&#x02013;<xref ref-type="bibr" rid="B58">58</xref>]. Studies on human brain biopsy
tissue indicated that several serine and threonine residues of tau
are normally phosphorylated at substoichiometrical levels
[<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>]. A normal level of phosphorylation appears to be
required for tau's optimal function, whereas the
hyperphosphorylated tau loses its biological activity [<xref ref-type="bibr" rid="B15">15</xref>,
<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B61">61</xref>&#x02013;<xref ref-type="bibr" rid="B69">69</xref>].</p></sec><sec sec-type="abnormal hyperphosphorylation of tau in  ad brain"><title>ABNORMAL HYPERPHOSPHORYLATION OF TAU IN  AD BRAIN</title><p>The discovery that tau aggregated in AD brain is abnormally
hyperphosphorylated has stimulated many studies on the extent and
sites of tau hyperphosphorylation and their role in the
pathogenesis of AD. The phosphorylation level of tau isolated from
autopsied AD brains is 3- to 4-fold higher than that from normal
human brains [<xref ref-type="bibr" rid="B56">56</xref>&#x02013;<xref ref-type="bibr" rid="B58">58</xref>]. In addition, the hyperphosphorylated
tau is accumulated in both brains [<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>] and cerebral
spinal fluid [<xref ref-type="bibr" rid="B72">72</xref>&#x02013;<xref ref-type="bibr" rid="B80">80</xref>] of individuals with
AD. All six isoforms of tau are aggregated into PHFs in the
abnormally hyperphosphorylated forms in AD brains [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B81">81</xref>]. To date, at least 37 serine and threonine residues have been
found to be phosphorylated in PHF-tau (for review, see [<xref ref-type="bibr" rid="B82">82</xref>]).
These residues include Thr39, Ser46, Thr69, Thr123, Ser137,
Thr153, Thr175, Thr181, Ser198, Ser199, Ser202, Thr205, Ser208,
Ser210, Thr212, Ser214, Thr217, Thr231, Ser235, Ser237, Ser238,
Ser241, Ser262, Ser285, Ser305, Ser324, Ser352, Ser356, Ser396,
Ser400, Thr403, Ser404, Ser409, Ser412, Ser413, Ser416, and
Ser422. Many of these residues are also phosphorylated in normal
human brains without NFTs at smaller extents, but they are rapidly
dephosphorylated during postmortem delay and tissue processing
[<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>]. However, the phosphate groups at these sites are
not readily dephosphorylated during the postmortem period and
tissue processing of AD brain, probably because of the deficient
protein phosphatase activities [<xref ref-type="bibr" rid="B83">83</xref>&#x02013;<xref ref-type="bibr" rid="B89">89</xref>]. Some of the phosphorylation sites seen in PHF-tau are not phosphorylated at all in normal brains. These sites include Thr212/Ser214, Thr231/Ser235 [<xref ref-type="bibr" rid="B90">90</xref>], and Ser422 [<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>].</p><p>Because all of the previously identified phosphorylation sites of
normal tau and PHF-tau are at either serine or threonine residues,
it was thought that tau was phosphorylated only at serine and
threonine residues. However, recent studies suggest that tau in
developing brain and in AD brain is also phosphorylated at
tyrosine residues. The src-family nonreceptor tyrosine kinase fyn
can bind to and phosphorylate tau in vitro and in transfected
cells [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. The phosphorylation site of tau was
mapped as Tyr18. Tyrosine phosphorylated tau at this position is
also seen immunohistochemically in the brain of transgenic mice
that express mutated human tau<sub>P301L</sub> [<xref ref-type="bibr" rid="B51">51</xref>].
Williamson et al [<xref ref-type="bibr" rid="B94">94</xref>] demonstrated that in primary human and rat brain cortical cultures tau is phosphorylated at Tyr 29 upon
treatment with A&#x003b2;. The tyrosine phosphorylation of tau
appears rapid and transient. Interestingly, antibodies specific to
tyrosine phosphorylated tau labeled purified PHF-tau, but not
normal tau, suggesting that PHF-tau is phosphorylated at the
tyrosine residues [<xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>]. In addition, Tyr394 was also
found to be phosphorylated in PHF-tau and in tau from fetal
brains, and the phosphorylation at this site is catalyzed by
another nonreceptor tyrosine kinase <italic>c</italic>-Abl [<xref ref-type="bibr" rid="B95">95</xref>]. It is not
clear if the phosphorylation at any of the above tyrosine residues
is stoichiometrically significant. Therefore, whether the tyrosine
phosphorylation of tau has any pathophysiological relevance
remains to be elucidated.</p><p>Numerous studies have demonstrated the important role of abnormal
hyperphosphorylation of tau in its aggregation into NFTs and in
Alzheimer's neurofibrillary degeneration. In cultured cells,
hyperphosphorylation of tau after treatment with phosphatase
inhibitors impairs its activity to bind to microtubules and
induces filamentous aggregation of tau [<xref ref-type="bibr" rid="B21">21</xref>].
Pseudohyperphosphorylated tau that simulates abnormally
hyperphosphorylated tau by mutation of serine or threonine
residues into glutamate at selected AD-related sites exerts a
cytotoxic effect, whereas wild-type tau is neutral [<xref ref-type="bibr" rid="B22">22</xref>]. In
contrast, neurons from tau-knockout mice are resistant to A&#x003b2;-induced neurotoxicity [<xref ref-type="bibr" rid="B96">96</xref>]. Overexpression of human tau in
combination with phosphorylation by Drosophila GSK-3&#x003b2; homologue Shaggy, but not tau overexpression alone, exacerbates
tau-induced neurodegeneration and results in the formation of
NFT-like filamentous tau aggregates [<xref ref-type="bibr" rid="B23">23</xref>]. This study shows a
causal relationship between tau hyperphosphorylation and
neurofibrillary degeneration in vivo. A study in Disabled-1 (an
adapter protein) knockout mice further demonstrates that tau
hyperphosphorylation causes early death of the animals [<xref ref-type="bibr" rid="B97">97</xref>].
Most importantly, tau in inclusions of all tauopathies in human
and animal models is always hyperphosphorylated (for reviews, see
[<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B98">98</xref>]). Abnormal hyperphosphorylation of tau appears to
precede its aggregation into NFTs in AD brain [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B99">99</xref>&#x02013;<xref ref-type="bibr" rid="B101">101</xref>]. Taken together, these studies suggest that the
abnormal hyperphosphorylation of tau is crucial to neurofibrillary
degeneration in AD and other tauopathies.
</p><p>The largest isoform of human brain tau (441 amino acids) contains
80 serine and threonine residues and five tyrosine residues
[<xref ref-type="bibr" rid="B31">31</xref>]. Phosphorylation at nearly half of these residues has
been reported in PHF-tau (see [<xref ref-type="bibr" rid="B82">82</xref>] for review). Many studies
have demonstrated that phosphorylation of tau at different sites
has different impacts on its biological function and on its
pathogenic role. For instance, a quantitative in vitro study
demonstrated that phosphorylation of tau at Ser262, Thr231, and
Ser235 inhibits its binding to microtubules by &#x0223c;35%,
&#x0223c;25%, and 10%, respectively [<xref ref-type="bibr" rid="B102">102</xref>]. In cultured
cells, phosphorylation of tau at Ser214 and Ser262 decreases its
binding to microtubules and appears to inhibit its assembly to
filaments [<xref ref-type="bibr" rid="B103">103</xref>]. In vitro kinetic studies of the binding
between hyperphosphorylated tau and normal tau suggest that
phosphorylation of tau at Ser199/Ser202/Thr205, Thr212,
Thr231/Ser235, Ser262/Ser356, and Ser422 are among the critical
phosphorylation sites that convert tau to a toxic molecule to
sequester normal MAPs from microtubules [<xref ref-type="bibr" rid="B19">19</xref>]. Further
phosphorylation at Thr231, Ser396, and Ser422 promotes
self-assembly of tau into filaments. Similarly, tau mutated at
Ser396 and Ser404 (changing Ser into Glu) to mimic phosphoserine
is more fibrillogenic than wild-type tau [<xref ref-type="bibr" rid="B104">104</xref>], and a tau
construct in which Ser422 is mutated to Glu shows a significantly
increased propensity to aggregate [<xref ref-type="bibr" rid="B105">105</xref>]. Consistent with
these observations is that mutation of Ser422 to Ala prevents
A&#x003b2;-induced tau aggregation [<xref ref-type="bibr" rid="B106">106</xref>]. These results
suggest that phosphorylation of Ser422 may play a key role in tau
filament formation in vivo.
</p><p>An important question is, by what mechanism is the tau abnormality
involved in the pathological cascades that lead to
neurodegeneration in AD and other tauopathies. Does a
hyperphosphorylation-induced defect in its activity to stimulate
microtubule-assembly contribute to cell dysfunction? Is it the
formation of insoluble tau aggregates that is pathogenic? Although
tau loses its activity to stimulate microtubules, lack of overt
phenotype of tau knockout transgenic mice [<xref ref-type="bibr" rid="B107">107</xref>] suggests that
it is very unlikely that tau abnormality contributes to
neurodegeneration via loss of normal function due to its
hyperphosphorylation. By a series of studies, we have found that
both the abnormally hyperphosphorylated tau isolated from AD brain
and in vitro hyperphosphorylation tau gain a toxic activity to
sequester normal tau and other MAPs, such as MAP1 and MAP2, and
cause microtubule disassembly [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B108">108</xref>]. Upon
dephosphorylation, they lose this toxic activity. Polymerization
of the hyperphosphorylated tau into PHFs also abolishes this toxic
activity (Alonso A et al, unpublished observation). Hence, we
speculate that the abnormal hyperphosphorylation of tau causes
neurodegeneration by gain of toxic activity rather than by loss of
normal activity that can be compensated for by other MAPs and that
formation of PHFs/NFTs from the hyperphosphorylated tau in neurons
is a defense mechanism by which neurons aim to reduce the toxic
activity of the abnormally hyperphosphorylated tau. This
speculation is supported by recent in vivo studies. Conditional
overexpression of GSK-3&#x003b2; in the transgenic mouse brains
induces tau hyperphosphorylation and neurodegeneration, but no tau
aggregation [<xref ref-type="bibr" rid="B109">109</xref>]. In contrast, there are NFTs but no memory
loss in several lines of tau transgenic mice (for review, see
[<xref ref-type="bibr" rid="B110">110</xref>]). This phenomenon is probably common to other diseases
characterized by abnormal protein aggregates such as Huntington
disease and cardiomyopathy, in which the abnormal, nonfibrillar
protein oligomers, rather than the aggregates themselves, appear
to be pathogenic [<xref ref-type="bibr" rid="B111">111</xref>, <xref ref-type="bibr" rid="B112">112</xref>].</p></sec><sec sec-type="imbalance of phosphorylation/dephosphorylation in ad brain"><title>IMBALANCE OF PHOSPHORYLATION/DEPHOSPHORYLATION IN AD BRAIN</title><p>To understand the mechanism leading to abnormal
hyperphosphorylation of tau in AD, protein kinases and
phosphatases that regulate tau phosphorylation level must be
identified first. In the last two decades, numerous studies aimed
to the identification of tau kinases and phosphatases have been
carried out. It was found that in vitro, dozens of
phosphoseryl/phosphothroenyl protein kinases and most of the major
protein phosphatases could act on tau protein at various
phosphorylation sites (for reviews in detail, see [<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>]). Tau appears to be a universal substrate for protein kinases
and phosphatases in vitro. This may not be surprising, because
nearly 20% of the amino acid residues of tau molecule are serines
and threonines, and nearly 50% of these residues are
phosphorylated to certain degrees in AD brain (see [<xref ref-type="bibr" rid="B82">82</xref>] for
review). However, it is unlikely that all these enzymes that act
on tau in vitro catalyze tau phosphorylation/dephosphorylation in
vivo. Immunohistochemical studies also have shown a colocalization
of more than a dozen protein kinases and several protein
phosphatases with NFTs of AD brain. As we now know that NFTs are
very &#x0201c;sticky&#x0201d; structures that can be stained
immunohistochemically by antibodies to numerous antigens,
immunohistochemical colocalization with NFTs can only support
other data that indicate a role of the specific protein or enzyme
in the formation of NFTs, but itself cannot indicate such a role.</p><p>Further studies in cultured cells, in situ, and especially in vivo
suggest that a few protein kinases and phosphatases may be
involved in regulation of tau phosphorylation in the brain. The
kinases that most likely play a role in phosphorylation of tau in
the brain include glycogen synthase kanase-3&#x003b2; (GSK-3&#x003b2;), cyclin-dependent kinase 5 (cdk5), cAMP-dependent
protein kinase (PKA), stress-activated protein kinases, and
calcium/calmodulin-dependent kinase II (CaMK-II). Johnson and
Stoothoff [<xref ref-type="bibr" rid="B115">115</xref>] have critically discussed this issue. The
sites of tau phosphorylation by these kinases, except
stress-activity protein kinases, have been summarized in our
recent review [<xref ref-type="bibr" rid="B82">82</xref>]. Among protein phosphatases, PP2A has been
shown to be the major tau phosphatase in the brain [<xref ref-type="bibr" rid="B69">69</xref>,
<xref ref-type="bibr" rid="B116">116</xref>&#x02013;<xref ref-type="bibr" rid="B120">120</xref>]. In a recent study, we compared the catalytic
kinetics of tau dephosphorylation by various major brain protein
phosphatases and determined the relative contributions of these
phosphatases to the regulation of tau phosphorylation
quantitatively. We found that PP2A accounts for &#x0223c;70% of
the total tau phosphatase activity, whereas PP1, PP2B, and PP5
each accounts for only &#x0223c;10% of the total tau phosphatase
activity [<xref ref-type="bibr" rid="B88">88</xref>]. Because PP2B activity is upregulated rather
than downregulated in AD brain, it is unlikely that it regulates
tau phosphorylation in vivo [<xref ref-type="bibr" rid="B121">121</xref>].</p><p>Accumulated evidence indicates that tau phosphorylation is
regulated by several protein kinases and that more than one kinase
might be involved in abnormal hyperphosphorylation of tau in AD
brain. Interestingly, GSK-3&#x003b2; phosphorylates tau at both
prime sites (ie, tau needs to be primed by phosphorylation with
other kinases at other sites) and unprimed sites
[<xref ref-type="bibr" rid="B122">122</xref>&#x02013;<xref ref-type="bibr" rid="B126">126</xref>]. In a cotransfection study,
Cho and Johnson [<xref ref-type="bibr" rid="B125">125</xref>] found that a GSK-3&#x003b2;
mutant (GSK-3&#x003b2;-R96A) that only phosphorylates unprimed sites has no
negative impact on tau's ability to bind to microtubules, in
contrast to wild-type GSK-3&#x003b2;, which significantly impairs
tau's ability to bind to microtubules. Further studies demonstrate
that primed phosphorylation of tau at Thr231 by GSK-3&#x003b2; plays a critical role in decreasing tau's ability to both bind to
and stabilize microtubules [<xref ref-type="bibr" rid="B126">126</xref>]. In rat brains, activation of PKA not only induces primed phosphorylation of tau by
GSK-3&#x003b2;, but also impairs the spatial memory of rats
[<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B127">127</xref>]. GSK-3&#x003b2; appears to be regulated by both
phosphoinositol-3 kinase and protein kinase <italic>C</italic>
 pathways
[<xref ref-type="bibr" rid="B128">128</xref>&#x02013;<xref ref-type="bibr" rid="B131">131</xref>].</p><p>An obvious approach to understanding how tau becomes abnormally
hyperphosphorylated in AD is to study whether tau kinase(s) or tau
phosphatase(s) are dysregulated in AD brain. Several studies have
focused on whether the activities and expression of these enzymes
are altered in AD brain. Among protein kinases, cdk5 was reported
to be upregulated in AD brain by one laboratory [<xref ref-type="bibr" rid="B132">132</xref>], but
this result was challenged by others [<xref ref-type="bibr" rid="B133">133</xref>&#x02013;<xref ref-type="bibr" rid="B136">136</xref>]. On
the other hand, both the activity and the expression of PP2A as
well as the activities of PP1 and PP5 are decreased in the
selected areas of AD brain [<xref ref-type="bibr" rid="B83">83</xref>&#x02013;<xref ref-type="bibr" rid="B89">89</xref>]. Consistent with this finding, several other neuronal proteins such as neurofilaments, MAP1B, &#x003b2;-tubulin, and &#x003b2;-catenin are
also hyperphosphorylated in AD brain [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>]. Hence, it
appears that downregulation of the phosphatases, especially of
PP2A, might underlie the abnormal hyperphosphorylation of tau and
other proteins in AD brain. Studies of metabolically active rat
brain slices and transgenic mice suggest that the downregulation
of PP2A may produce hyperphosphorylation of tau, not only by the
deficient dephosphorylation of tau, but also through the
activation of several PP2A-regulated protein kinases, including
PKA [<xref ref-type="bibr" rid="B137">137</xref>], CaMK-II [<xref ref-type="bibr" rid="B138">138</xref>], MAP kinases, and
stress-activated protein kinases [<xref ref-type="bibr" rid="B139">139</xref>&#x02013;<xref ref-type="bibr" rid="B141">141</xref>]. Nevertheless,
inhibition of PP2A activity in animal brain could only induce
hyperphosphorylation of tau at some of the hyperphosphorylation
sites seen in PHF-tau, but does not result in NFTs. Attempts to
produce massive tangles of PHFs in animal models merely via
alteration of tau phosphatase and/or kinase activities have not
yet been successful. These observations suggest that the
downregulation of tau phosphatases in AD brain may be only
partially responsible for the abnormal hyperphosphorylation of
tau.</p><p>The causes leading to decreased PP2A activity in AD brain are not
well understood. Downregulation of PP2A expression [<xref ref-type="bibr" rid="B85">85</xref>] and
upregulation of PP2A endogenous inhibitor proteins
<mml:math id="M1"><mml:mrow><mml:msubsup><mml:mtext>I</mml:mtext><mml:mtext>1</mml:mtext><mml:mrow><mml:mtext>PP2A</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:math> and <mml:math id="M2"><mml:mrow><mml:msubsup><mml:mtext>I</mml:mtext><mml:mtext>2</mml:mtext><mml:mrow><mml:mtext>PP2A</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:math> [<xref ref-type="bibr" rid="B142">142</xref>] in AD
brain may both contribute to the downregulation of PP2A activity.
Because the activities of PP1 [<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B88">88</xref>] and PP5 [<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>],
which contribute to regulation of tau phosphorylation to a much
smaller extent than PP2A [<xref ref-type="bibr" rid="B88">88</xref>], are also decreased in AD
brain, there might be a common factor that downregulates the
activities of the major brain protein phosphatases in AD brain.</p><p>In addition to tau kinases and phosphatases, alterations of tau
itself, the substrate of these enzymes, may also play an important
role in its abnormal hyperphosphorylation and conversion into
PHFs. Tau is also modified post-translationally by
&#x003b2;-<italic>N</italic>-acetylglucosamine (GlcNAc) via a glycosidic bond at
the hydroxyl groups of serine and/or threonine residues, and this
modification is called <italic>O</italic>-GlcNAcylation [<xref ref-type="bibr" rid="B143">143</xref>&#x02013;<xref ref-type="bibr" rid="B145">145</xref>].
Because <italic>O</italic>-GlcNAc could modify the same serine or threonine
residues of tau as phosphate does and a reciprocal relationship
between <italic>O</italic>-GlcNAcylation and phosphorylation has been seen in
many proteins (for review, see [<xref ref-type="bibr" rid="B146">146</xref>]), <italic>O</italic>-GlcNAcylation
could affect phosphorylation of tau. Recent studies in various
systems found that tau phosphorylation is indeed regulated by
<italic>O</italic>-GlcNAcylation inversely [<xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B147">147</xref>]. Most
interestingly, fasting of mice induces downregulation of tau
<italic>O</italic>-GlcNAcylation, which relies on glucose metabolism to supply
UDP-GlcNAc as a donor for protein <italic>O</italic>-GlcNAcylation, and in turn
leads to hyperphosphorylation of tau [<xref ref-type="bibr" rid="B145">145</xref>]. These findings
led to the novel hypothesis that impaired glucose
uptake/metabolism in AD brain, which was well established decades
ago, contributes to the disease pathogenesis via downregulation of
tau <italic>O</italic>-GlcNAcylation and, consequently, upregulation of tau
phosphorylation that leads to neurofibrillary degeneration
[<xref ref-type="bibr" rid="B148">148</xref>].</p><p>Classical <italic>N</italic>-linked glycosylation is a modification of protein at
asparagine residues by oligosaccharides, which normally modifies
only membrane proteins and secreted proteins. Tau in AD brain, but
not in normal human brain, was found to be modified by
<italic>N</italic>-glycosylation [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B149">149</xref>, <xref ref-type="bibr" rid="B150">150</xref>], and this aberrant tau modification appears to precede and facilitate abnormal
hyperphosphorylation of tau [<xref ref-type="bibr" rid="B150">150</xref>&#x02013;<xref ref-type="bibr" rid="B152">152</xref>]. This modification has been reviewed in detail in a recent article
[<xref ref-type="bibr" rid="B82">82</xref>].</p></sec><sec sec-type="mechanism of neurofibrillary degeneration"><title>MECHANISM OF NEUROFIBRILLARY DEGENERATION</title><p>There is no doubt that the abnormality of tau plays a central role
in neurofibrillary degeneration in AD and other tauopathies. A
critical review of the literature accumulated in the last two
decades sheds light onto the probable mechanism of neurofibrillary
degeneration of AD (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><p>Tau is the major microtubule-associated protein of mature neurons
where it stimulates microtubule assembly and stabilizes
microtubule structure. Tau is normally modified by both
phosphorylation and <italic>O</italic>-GlcNAcylation. The phosphorylation level
of tau is regulated by tau kinases and tau phosphatases, as well
as by the alteration of tau itself. In AD and probably also in
other tauopathies, metabolic and genetic abnormalities lead to
dysregulation of signal transduction pathways, which in turn
causes an imbalance of the phosphorylation/dephosphorylation
system, that is, downregulation of PP2A in the brain. This
imbalance results in increased phosphorylation (ie,
hyperphosphorylation) of tau. The impaired brain glucose
uptake/metabolism that precedes AD also facilitates
hyperphosphorylation of tau via downregulation of tau
<italic>O</italic>-GlcNAcylation [<xref ref-type="bibr" rid="B148">148</xref>]. Aberrant <italic>N</italic>-glycosylation of tau in
AD brain also makes tau a more favorable substrate for major tau
kinases and less favorable for tau phosphatases [<xref ref-type="bibr" rid="B151">151</xref>, <xref ref-type="bibr" rid="B152">152</xref>],
thereby facilitating tau hyperphosphorylation.
</p><p>The abnormally hyperphosphorylated tau resulting from any of the
above causes not only loses its biological activity to stimulate
microtubule assembly, but also becomes a toxic molecule,
sequesters normal tau, MAP1, and MAP2, and causes disassembly of
microtubules. The breakdown of the microtubule network in the
affected neurons compromises axonal transport and leads to
retrograde degeneration, which in turn results in neuronal death
and dementia. On the other hand, the abnormally
hyperphosphorylated tau detached from microtubules is not only
easier to polymerize into PHFs as a result of
hyperphosphorylation, but it also causes increased intraneuronal
soluble tau concentration due to sequestration of normal tau from
microtubules, which further facilitates tau aggregation into PHFs.
The polymerized abnormal tau is further modified by
ubiquitination, glycation, polyamination, nitration, and
truncation (for review, see [<xref ref-type="bibr" rid="B82">82</xref>]), and forms mature
PHFs/NFTs. Unlike the unpolymerized hyperphosphorylated tau that
is toxic, PHFs/NFTs appears to be inert (Alonso A et al unpublished observation), but these lesions grow in size
with disease progression and eventually might physically choke the
affected neuron to death.</p></sec><sec sec-type="therapeutic target to treat ad by correcting dysregulation of protein phosphorylation/dephosphorylation"><title>THERAPEUTIC TARGET TO TREAT AD BY CORRECTING DYSREGULATION OF PROTEIN PHOSPHORYLATION/DEPHOSPHORYLATION</title><p>Because neurofibrillary degeneration plays a central role in the
pathogenesis of AD, one of the most attractive therapeutic targets
of AD is to inhibit neurofibrillary degeneration. As outlined in
<xref ref-type="fig" rid="F1">Figure 1</xref>, the most promising approaches to achieve
this goal are to inhibit the abnormal hyperphosphorylation of tau
and to inhibit its sequestration of normal MAPs. The former
approach is more effective since it should both rescue the
disruption of microtubule and axoplasmic flow and prevent further
deposition of NFTs. Several academic groups and pharmaceutical
companies have been investigating this approach by restoring PP2A
activity or inhibiting tau kinase activity in the brain.
Memantine, a low-to-moderate-affinity antagonist of NMDA receptor,
which improves mental function and the quality of daily life of
individuals with moderate to severe AD [<xref ref-type="bibr" rid="B153">153</xref>, <xref ref-type="bibr" rid="B154">154</xref>], reverses
the okadaic-acid-induced inhibition of PP2A activity and prevents
tau hyperphosphorylation in hippocampal slice cultures from adult
rats [<xref ref-type="bibr" rid="B155">155</xref>]. The restoration of PP2A activity to normal level
by memantine also leads to restoration of the expression of MAP2
in the neuropil and a reversal of hyperphosphorylation and
accumulation of neurofilaments. Wang's group has demonstrated that
treatment of brain slices and rats with melatonin can restore PP2A
activity that is inhibited by okadaic acid or calyculin A and
reverse hyperphosphorylation of tau and neurofilament proteins as
well as cytotoxicities [<xref ref-type="bibr" rid="B156">156</xref>&#x02013;<xref ref-type="bibr" rid="B158">158</xref>]. Melatonin also prevents
tau hyperphosphorylation and aggregation induced by overactivation
of GSK-3 or PKA [<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B159">159</xref>]. These are examples showing that
inhibition of dysregulation of protein
phosphorylation/dephosphorylation is a promising target to treat
AD. Further investigation of new compounds that can inhibit
abnormal hyperphosphorylation of tau will likely provide new
treatments for AD.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We are grateful to J Biegelson and S Warren for secretarial
assistance and to M Marlow for editorial suggestions. This work
was supported in part by the New York State Office of Mental
Retardation and Developmental Disabilities and grants from
National Institutes of Health (AG16760 to C-X Gong, AG19158 to K
Iqbal), the Alzheimer's Association, Chicago, Ill (NIRG-03-4721 to
F Liu, IIRG-05-13095 to C-X Gong), and the Li Foundation, New York
(to C-X Gong).</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glenner</surname><given-names>GG</given-names></name><name><surname>Wong</surname><given-names>CW</given-names></name></person-group><article-title>Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1984</year><volume>120</volume><issue>3</issue><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">6375662</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Simms</surname><given-names>G</given-names></name><name><surname>Weinman</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1985</year><volume>82</volume><issue>12</issue><fpage>4245</fpage><lpage>4249</lpage><pub-id pub-id-type="pmid">3159021</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Quinlan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microtubule-associated protein tau. A component of Alzheimer paired helical filaments</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1986</year><volume>261</volume><issue>13</issue><fpage>6084</fpage><lpage>6089</lpage><pub-id pub-id-type="pmid">3084478</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1986</year><volume>83</volume><issue>13</issue><fpage>4913</fpage><lpage>4917</lpage><pub-id pub-id-type="pmid">3088567</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>BE</given-names></name><name><surname>Blessed</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Observations on the brains of demented old people</article-title><source><italic>Journal of the Neurological Sciences</italic></source><year>1970</year><volume>11</volume><issue>3</issue><fpage>205</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">5505685</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Friden</surname><given-names>H</given-names></name><name><surname>Adolfsson</surname><given-names>R</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name></person-group><article-title>Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis</article-title><source><italic>Acta Neuropathologica (Berl)</italic></source><year>1987</year><volume>74</volume><issue>3</issue><fpage>209</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">3673513</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Farlo</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><etal/></person-group><article-title>Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques</article-title><source><italic>The American Journal of Pathology</italic></source><year>1988</year><volume>132</volume><issue>1</issue><fpage>86</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">2456021</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arriagada</surname><given-names>PV</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease</article-title><source><italic>Neurology</italic></source><year>1992</year><volume>42</volume><issue>3 pt 1</issue><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">1549228</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>KP</given-names></name><name><surname>Snowdon</surname><given-names>DA</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group><article-title>Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study</article-title><source><italic>Annals of Neurology</italic></source><year>2002</year><volume>51</volume><issue>5</issue><fpage>567</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">12112102</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yancopoulou</surname><given-names>D</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name></person-group><article-title>Tau protein in familial and sporadic diseases</article-title><source><italic>Neuromolecular Medicine</italic></source><year>2003</year><volume>4</volume><issue>1&#x02013;2</issue><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">14528051</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tau pathology in Alzheimer disease and other tauopathies</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2005</year><volume>1739</volume><issue>2-3</issue><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">15615638</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Lendon</surname><given-names>CL</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Association of missense and 5&#x02032;-splice-site mutations in tau with the inherited dementia FTDP-17</article-title><source><italic>Nature</italic></source><year>1998</year><volume>393</volume><issue>6686</issue><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">9641683</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poorkaj</surname><given-names>P</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Wijsman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tau is a candidate gene for chromosome 17 frontotemporal dementia</article-title><source><italic>Annals of Neurology</italic></source><year>1998</year><volume>43</volume><issue>6</issue><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">9629852</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Murrell</surname><given-names>JR</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutation in the tau gene in familial multiple system tauopathy with presenile dementia</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1998</year><volume>95</volume><issue>13</issue><fpage>7737</fpage><lpage>7741</lpage><pub-id pub-id-type="pmid">9636220</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Defective brain microtubule assembly in Alzheimer's disease</article-title><source><italic>Lancet</italic></source><year>1986</year><volume>2</volume><issue>8504</issue><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">2874414</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Role of abnormally phosphorylated &#x003c4; in the breakdown of microtubules in Alzheimer disease</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1994</year><volume>91</volume><issue>12</issue><fpage>5562</fpage><lpage>5566</lpage><pub-id pub-id-type="pmid">8202528</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2001</year><volume>98</volume><issue>12</issue><fpage>6923</fpage><lpage>6928</lpage><pub-id pub-id-type="pmid">11381127</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>41</issue><fpage>37967</fpage><lpage>37973</lpage><pub-id pub-id-type="pmid">11495914</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Mederlyova</surname><given-names>A</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Promotion of hyperphosphorylation by frontotemporal dementia tau mutations</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2004</year><volume>279</volume><issue>33</issue><fpage>34873</fpage><lpage>34881</lpage><pub-id pub-id-type="pmid">15190058</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>JJ</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Gomez-Ramos</surname><given-names>P</given-names></name><etal/></person-group><article-title>Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice</article-title><source><italic>The EMBO Journal</italic></source><year>2001</year><volume>20</volume><issue>1-2</issue><fpage>27</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">11226152</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Gomez-Ramos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Formation
of aberrant phosphotau fibrillar polymers in neural cultured cells</article-title><source><italic>European Journal of Biochemistry</italic></source><year>2002</year><volume>269</volume><issue>5</issue><fpage>1484</fpage><lpage>1489</lpage><pub-id pub-id-type="pmid">11874463</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fath</surname><given-names>T</given-names></name><name><surname>Eidenmuller</surname><given-names>J</given-names></name><name><surname>Brandt</surname><given-names>R</given-names></name></person-group><article-title>Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2002</year><volume>22</volume><issue>22</issue><fpage>9733</fpage><lpage>9741</lpage><pub-id pub-id-type="pmid">12427828</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>GR</given-names></name><name><surname>Wiedau-Pazos</surname><given-names>M</given-names></name><name><surname>Sang</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila</article-title><source><italic>Neuron</italic></source><year>2002</year><volume>34</volume><issue>4</issue><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">12062036</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stemberger</surname><given-names>NH</given-names></name><name><surname>Sternberger</surname><given-names>LA</given-names></name><name><surname>Ulrich</surname><given-names>J</given-names></name></person-group><article-title>Aberrant neurofilament phosphorylation in Alzheimer disease</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1985</year><volume>82</volume><fpage>4274</fpage><lpage>4276</lpage><pub-id pub-id-type="pmid">3159022</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulloa</surname><given-names>L</given-names></name><name><surname>de Garcini</surname><given-names>EM</given-names></name><name><surname>G&#x000f2;mez-Ramos</surname><given-names>P</given-names></name><etal/></person-group><article-title>Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer's disease patients</article-title><source><italic>Molecular Brain Research</italic></source><year>1994</year><volume>26</volume><issue>1-2</issue><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">7854037</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vijayan</surname><given-names>S</given-names></name><name><surname>El-Akkad</surname><given-names>E</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>A pool of &#x003b2;-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain</article-title><source><italic>FEBS Letters</italic></source><year>2001</year><volume>509</volume><issue>3</issue><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">11749959</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J-Z</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells</article-title><source><italic>FEBS Letters</italic></source><year>2001</year><volume>507</volume><issue>1</issue><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">11682063</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weingarten</surname><given-names>MD</given-names></name><name><surname>Lockwood</surname><given-names>AH</given-names></name><name><surname>Hwo</surname><given-names>S-Y</given-names></name><etal/></person-group><article-title>A protein factor essential for microtubule assembly</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1975</year><volume>72</volume><issue>5</issue><fpage>1858</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">1057175</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Balin</surname><given-names>BJ</given-names></name><name><surname>Otvos</surname><given-names>L</given-names><suffix>Jr</suffix></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>A68: a major subunit of paired helical filaments and derivatized forms of normal Tau</article-title><source><italic>Science</italic></source><year>1991</year><volume>251</volume><issue>4994</issue><fpage>675</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">1899488</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Harris</surname><given-names>P</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2</article-title><source><italic>Brain Research</italic></source><year>1986</year><volume>387</volume><issue>3</issue><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">3103857</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease</article-title><source><italic>Neuron</italic></source><year>1989</year><volume>3</volume><issue>4</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">2484340</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>The microtubule binding domain of tau protein</article-title><source><italic>Neuron</italic></source><year>1989</year><volume>2</volume><issue>6</issue><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">2516729</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>BL</given-names></name><name><surname>Feinstein</surname><given-names>SC</given-names></name></person-group><article-title>Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau</article-title><source><italic>The Journal of Cell Biology</italic></source><year>1994</year><volume>124</volume><issue>5</issue><fpage>769</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">8120098</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>D</given-names></name><name><surname>Goode</surname><given-names>BL</given-names></name><name><surname>Feinstein</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau</article-title><source><italic>Biochemistry</italic></source><year>1995</year><volume>34</volume><issue>35</issue><fpage>11117</fpage><lpage>11127</lpage><pub-id pub-id-type="pmid">7669769</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirokawa</surname><given-names>N</given-names></name><name><surname>Shiomura</surname><given-names>Y</given-names></name><name><surname>Okabe</surname><given-names>S</given-names></name></person-group><article-title>Tau proteins: the molecular structure and mode of binding on microtubules</article-title><source><italic>The Journal of Cell Biology</italic></source><year>1988</year><volume>107</volume><issue>4</issue><fpage>1449</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">3139677</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Leger</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name></person-group><article-title>Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain</article-title><source><italic>The Journal of Cell Biology</italic></source><year>1995</year><volume>131</volume><issue>5</issue><fpage>1327</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">8522593</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Utton</surname><given-names>MA</given-names></name><name><surname>Gibb</surname><given-names>GM</given-names></name><name><surname>Burdett</surname><given-names>ID</given-names></name><etal/></person-group><article-title>Functional differences of tau isoforms containing 3 or 4 C-terminal repeat regions and the influence of oxidative stress</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>36</issue><fpage>34288</fpage><lpage>34297</lpage><pub-id pub-id-type="pmid">11438517</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanford</surname><given-names>PM</given-names></name><name><surname>Shepherd</surname><given-names>CE</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia</article-title><source><italic>Brain</italic></source><year>2003</year><volume>126</volume><issue>pt 4</issue><fpage>814</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">12615641</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosik</surname><given-names>KS</given-names></name><name><surname>Orecchio</surname><given-names>LD</given-names></name><name><surname>Bakalis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Developmentally regulated expression of specific tau sequences</article-title><source><italic>Neuron</italic></source><year>1989</year><volume>2</volume><issue>4</issue><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">2560640</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name></person-group><article-title>Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization</article-title><source><italic>The EMBO Journal</italic></source><year>1990</year><volume>9</volume><issue>13</issue><fpage>4225</fpage><lpage>4230</lpage><pub-id pub-id-type="pmid">2124967</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tatebayashi</surname><given-names>Y</given-names></name><name><surname>Haque</surname><given-names>N</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Role of tau phosphorylation by glycogen synthase kinase-3&#x003b2; in the regulation of organelle transport</article-title><source><italic>Journal of Cell Science</italic></source><year>2004</year><volume>117</volume><issue>pt 9</issue><fpage>1653</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">15075227</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebneth</surname><given-names>A</given-names></name><name><surname>Godemann</surname><given-names>R</given-names></name><name><surname>Stamer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease</article-title><source><italic>The Journal of Cell Biology</italic></source><year>1998</year><volume>143</volume><issue>3</issue><fpage>777</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">9813097</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform</article-title><source><italic>Neuron</italic></source><year>1999</year><volume>24</volume><issue>3</issue><fpage>751</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">10595524</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spittaels</surname><given-names>K</given-names></name><name><surname>Van den Haute</surname><given-names>C</given-names></name><name><surname>Van Dorpe</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein</article-title><source><italic>The American Journal of Pathology</italic></source><year>1999</year><volume>155</volume><issue>6</issue><fpage>2153</fpage><lpage>2165</lpage><pub-id pub-id-type="pmid">10595944</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>McGowan</surname><given-names>E</given-names></name><name><surname>Rockwood</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein</article-title><source><italic>Nature Genetics</italic></source><year>2000</year><volume>25</volume><issue>4</issue><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">10932182</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>A</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name><name><surname>Wiederhold</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein</article-title><source><italic>Acta Neuropathologica (Berl)</italic></source><year>2000</year><volume>99</volume><issue>5</issue><fpage>469</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">10805089</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rendon</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Jancsik</surname><given-names>V</given-names></name></person-group><article-title>Interaction of microtubules and microtubule-associated proteins (MAPs) with rat brain mitochondria</article-title><source><italic>The Biochemical Journal</italic></source><year>1990</year><volume>269</volume><issue>2</issue><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">2386493</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kampers</surname><given-names>T</given-names></name><name><surname>Friedhoff</surname><given-names>P</given-names></name><name><surname>Biernat</surname><given-names>J</given-names></name><etal/></person-group><article-title>RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments</article-title><source><italic>FEBS Letters</italic></source><year>1996</year><volume>399</volume><issue>3</issue><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">8985176</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>RQ</given-names></name><name><surname>Haque</surname><given-names>N</given-names></name><etal/></person-group><article-title>Microtubule associated protein tau binds to double-stranded but not single-stranded DNA</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2003</year><volume>60</volume><issue>2</issue><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">12678504</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Newman</surname><given-names>ST</given-names></name><name><surname>Gard</surname><given-names>DL</given-names></name><name><surname>Band</surname><given-names>H</given-names></name><name><surname>Panchamoorthy</surname><given-names>G</given-names></name></person-group><article-title>Tau interacts with src-family non-receptor tyrosine kinases</article-title><source><italic>Journal of Cell Science</italic></source><year>1998</year><volume>111</volume><issue>pt 21</issue><fpage>3167</fpage><lpage>3177</lpage><pub-id pub-id-type="pmid">9763511</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhaskar</surname><given-names>K</given-names></name><name><surname>Yen</surname><given-names>S-H</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name></person-group><article-title>Disease-related modifications in
tau affect the interaction between Fyn and Tau</article-title><source><italic>The Journal
of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>42</issue><fpage>35119</fpage><lpage>35125</lpage><pub-id pub-id-type="pmid">16115884</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaspert</surname><given-names>A</given-names></name><name><surname>Fahsold</surname><given-names>R</given-names></name><name><surname>Grehl</surname><given-names>H</given-names></name><etal/></person-group><article-title>Myotonic dystrophy: correlation
of clinical symptoms with the size of the CTG trinucleotide
repeat</article-title><source><italic>Journal of Neurology</italic></source><year>1995</year><volume>242</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">7707098</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name></person-group><article-title>Tau complexes with phospholipase C-gamma in situ</article-title><source><italic>NeuroReport</italic></source><year>1998</year><volume>9</volume><issue>1</issue><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9592050</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Hwo</surname><given-names>SY</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><article-title>Physical and chemical
properties of purified tau factor and the role of tau in
microtubule assembly</article-title><source><italic>Journal of Molecular Biology</italic></source><year>1977</year><volume>116</volume><issue>2</issue><fpage>227</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">146092</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindwall</surname><given-names>G</given-names></name><name><surname>Cole</surname><given-names>RD</given-names></name></person-group><article-title>Phosphorylation affects the ability of
tau protein to promote microtubule assembly</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1984</year><volume>259</volume><issue>8</issue><fpage>5301</fpage><lpage>5305</lpage><pub-id pub-id-type="pmid">6425287</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ksiezak-Reding</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>WK</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Phosphate analysis
and dephosphorylation of modified tau associated with
paired helical filaments</article-title><source><italic>Brain Research</italic></source><year>1992</year><volume>597</volume><issue>2</issue><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">1472994</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;pke</surname><given-names>E</given-names></name><name><surname>Tung</surname><given-names>Y-C</given-names></name><name><surname>Shaikh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Microtubule-associated
protein tau. Abnormal phosphorylation of a non-paired helical
filament pool in Alzheimer disease</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1993</year><volume>268</volume><issue>32</issue><fpage>24374</fpage><lpage>24384</lpage><pub-id pub-id-type="pmid">8226987</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenessey</surname><given-names>A</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name></person-group><article-title>The extent of phosphorylation of fetal
tau is comparable to that of PHF-tau from Alzheimer paired
helical filaments</article-title><source><italic>Brain Research</italic></source><year>1993</year><volume>629</volume><issue>1</issue><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">8287279</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>ES</given-names></name><name><surname>Shin</surname><given-names>RW</given-names></name><name><surname>Billingsley</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Biopsy-derived
adult human brain tau is phosphorylated at many of the same
sites as Alzheimer's disease paired helical filament tau</article-title><source><italic>Neuron</italic></source><year>1994</year><volume>13</volume><issue>4</issue><fpage>989</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">7946342</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garver</surname><given-names>TD</given-names></name><name><surname>Harris</surname><given-names>KA</given-names></name><name><surname>Lehman</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Tau phosphorylation
in human, primate, and rat brain: evidence that a
pool of tau is highly phosphorylated in vivo and is rapidly
dephosphorylated in vitro</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1994</year><volume>63</volume><issue>6</issue><fpage>2279</fpage><lpage>2287</lpage><pub-id pub-id-type="pmid">7964748</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Bancher</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alzheimer paired helical
filaments. Restoration of the biological activity by dephosphorylation</article-title><source><italic>FEBS Letters</italic></source><year>1994</year><volume>349</volume><issue>1</issue><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">8045285</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drechsel</surname><given-names>DN</given-names></name><name><surname>Hyman</surname><given-names>AA</given-names></name><name><surname>Cobb</surname><given-names>MH</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name></person-group><article-title>Modulation
of the dynamic instability of tubulin assembly by the
microtubule-associated protein tau</article-title><source><italic>Molecular Biology of the
Cell</italic></source><year>1992</year><volume>3</volume><issue>10</issue><fpage>1141</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">1421571</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bramblett</surname><given-names>GT</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><etal/></person-group><article-title>Abnormal tau phosphorylation
at Ser396 in Alzheimer's disease recapitulates development
and contributes to reduced microtubule binding</article-title><source><italic>Neuron</italic></source><year>1993</year><volume>10</volume><issue>6</issue><fpage>1089</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">8318230</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name></person-group><article-title>Tau in paired helical filaments is
functionally distinct from fetal tau: assembly incompetence
of paired helical filament-tau</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1993</year><volume>61</volume><issue>3</issue><fpage>1183</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">8360683</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biernat</surname><given-names>J</given-names></name><name><surname>Gustke</surname><given-names>N</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phosphorylation of
Ser<sup>262</sup> strongly reduces binding of tau to microtubules: distinction
between PHF-like immunoreactivity and microtubule
binding</article-title><source><italic>Neuron</italic></source><year>1993</year><volume>11</volume><issue>1</issue><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">8393323</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Alzheimer's disease
hyperphosphorylated tau sequesters normal tau into
tangles of filaments and disassembles microtubules</article-title><source><italic>Nature Medicine</italic></source><year>1996</year><volume>2</volume><issue>7</issue><fpage>783</fpage><lpage>787</lpage></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J-Z</given-names></name><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dephosphorylation of
Alzheimer paired helical filaments by protein phosphatase-
2A and -2B</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1995</year><volume>270</volume><issue>9</issue><fpage>4854</fpage><lpage>4860</lpage><pub-id pub-id-type="pmid">7876258</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J-Z</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Glycosylation of
microtubule-associated protein tau: an abnormal posttranslational
modification in Alzheimer's disease</article-title><source><italic>Nature Medicine</italic></source><year>1996</year><volume>2</volume><issue>8</issue><fpage>871</fpage><lpage>875</lpage></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Lidsky</surname><given-names>T</given-names></name><name><surname>Wegiel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phosphorylation of
microtubule-associated protein tau is regulated by protein
phosphatase 2A in mammalian brain. Implications for neurofibrillary
degeneration in Alzheimer's disease</article-title><source><italic>The Journal
of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>8</issue><fpage>5535</fpage><lpage>5544</lpage><pub-id pub-id-type="pmid">10681533</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khatoon</surname><given-names>S</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Brain levels of
microtubule-associated protein tau are elevated in Alzheimer's
disease: a radioimmuno-slot-blot assay for nanograms
of the protein</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1992</year><volume>59</volume><issue>2</issue><fpage>750</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">1629745</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khatoon</surname><given-names>S</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Levels of normal
and abnormally phosphorylated tau in different cellular and
regional compartments of Alzheimer disease and control
brains</article-title><source><italic>FEBS Letters</italic></source><year>1994</year><volume>351</volume><issue>1</issue><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8076698</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohnken</surname><given-names>R</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Zinkowski</surname><given-names>R</given-names></name><etal/></person-group><article-title>Detection
of tau phosphorylated at threonine 231 in cerebrospinal
fluid of Alzheimer's disease patients</article-title><source><italic>Neuroscience Letters.</italic></source><year>2000</year><volume>287</volume><issue>3</issue><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">10863026</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phosphorylated tau in human
cerebrospinal fluid is a diagnostic marker for Alzheimer's
disease</article-title><source><italic>Neuroscience Letters</italic></source><year>1999</year><volume>270</volume><issue>2</issue><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10462105</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Kohnken</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tracking of
Alzheimer's disease progression with cerebrospinal fluid tau
protein phosphorylated at threonine 231</article-title><source><italic>Annals of Neurology</italic></source><year>2001</year><volume>49</volume><issue>4</issue><fpage>545</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">11310639</pub-id></citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Zinkowski</surname><given-names>R</given-names></name><etal/></person-group><article-title>Measurement of
phosphorylated tau epitopes in the differential diagnosis of
Alzheimer disease: a comparative cerebrospinal fluid study</article-title><source><italic>Archives of General Psychiatry</italic></source><year>2004</year><volume>61</volume><issue>1</issue><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">14706948</pub-id></citation></ref><ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Lanari</surname><given-names>A</given-names></name><name><surname>Amici</surname><given-names>S</given-names></name><etal/></person-group><article-title>CSF phosphorylated
tau is a possible marker for discriminating Alzheimer's disease
from dementia with Lewy bodies</article-title><source><italic>Neurological Sciences</italic></source><year>2001</year><volume>22</volume><issue>1</issue><fpage>77</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">11487210</pub-id></citation></ref><ref id="B77"><label>77</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Van Kerschaver</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Sissodia</surname><given-names>S</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name></person-group><article-title>CSF-phospho-tau (181P) as a promising marker for discriminating
Alzheimer's disease from dementia with Lewy bodies</article-title><source><italic>Alzheimer's Disease: Advances
in Etiology, Pathogenesis and Therapeutics</italic></source><year>2001</year><publisher-loc>Chichester, UK</publisher-loc><publisher-name>John Wiley &#x00026; Sons</publisher-name><fpage>285</fpage><lpage>291</lpage></citation></ref><ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Urakami</surname><given-names>K</given-names></name><etal/></person-group><article-title>Large-scale, multicenter
study of cerebrospinal fluid tau protein phosphorylated at
serine 199 for the antemortem diagnosis of Alzheimer's disease</article-title><source><italic>Annals of Neurology</italic></source><year>2001</year><volume>50</volume><issue>2</issue><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">11506396</pub-id></citation></ref><ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>YY</given-names></name><name><surname>He</surname><given-names>SS</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><etal/></person-group><article-title>Levels of nonphosphorylated
and phosphorylated tau in cerebrospinal fluid of
Alzheimer's disease patients : an ultrasensitive bienzymesubstrate-
recycle enzyme-linked immunosorbent assay</article-title><source><italic>The American Journal of Pathology</italic></source><year>2002</year><volume>160</volume><issue>4</issue><fpage>1269</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">11943712</pub-id></citation></ref><ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Zinkowski</surname><given-names>R</given-names></name><name><surname>Teipel</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Differential diagnosis
of Alzheimer disease with cerebrospinal fluid levels of tau
protein phosphorylated at threonine 231</article-title><source><italic>Archives of Neurology</italic></source><year>2002</year><volume>59</volume><issue>8</issue><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">12164722</pub-id></citation></ref><ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Tau proteins of
Alzheimer paired helical filaments: abnormal phosphorylation
of all six brain isoforms</article-title><source><italic>Neuron</italic></source><year>1992</year><volume>8</volume><issue>1</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">1530909</pub-id></citation></ref><ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Post-translational modifications of tau protein in Alzheimer's disease</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2005</year><volume>112</volume><issue>6</issue><fpage>813</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">15517432</pub-id></citation></ref><ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Singh</surname><given-names>TJ</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Phosphoprotein
phosphatase activities in Alzheimer disease brain</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1993</year><volume>61</volume><issue>3</issue><fpage>921</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">8395566</pub-id></citation></ref><ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Shaikh</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J-Z</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phosphatase
activity toward abnormally phosphorylated &#x003c4;: decrease in Alzheimer disease brain</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1995</year><volume>65</volume><issue>2</issue><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">7616230</pub-id></citation></ref><ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogelsberg-Ragaglia</surname><given-names>V</given-names></name><name><surname>Schuck</surname><given-names>T</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>PP2A mRNA expression is quantitatively decreased in
Alzheimer's disease hippocampus</article-title><source><italic>Experimental Neurology</italic></source><year>2001</year><volume>168</volume><issue>2</issue><fpage>402</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">11259128</pub-id></citation></ref><ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loring</surname><given-names>JF</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A gene expression profile of
Alzheimer's disease</article-title><source><italic>DNA and Cell Biology</italic></source><year>2001</year><volume>20</volume><issue>11</issue><fpage>683</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">11788046</pub-id></citation></ref><ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontag</surname><given-names>E</given-names></name><name><surname>Luangpirom</surname><given-names>A</given-names></name><name><surname>Hladik</surname><given-names>C</given-names></name><etal/></person-group><article-title>Altered expression
levels of the protein phosphatase 2A AB&#x003b1;C enzyme are associated
with Alzheimer disease pathology</article-title><source><italic>Journal of Neuropathology
and Experimental Neurology</italic></source><year>2004</year><volume>63</volume><issue>4</issue><fpage>287</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">15099019</pub-id></citation></ref><ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Contributions of protein
phosphatases PP1, PP2A, PP2B and PP5 to the regulation
of tau phosphorylation</article-title><source><italic>The European Journal of Neuroscience</italic></source><year>2005</year><volume>22</volume><issue>8</issue><fpage>1942</fpage><lpage>1950</lpage><pub-id pub-id-type="pmid">16262633</pub-id></citation></ref><ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Dephosphorylation of
tau by protein phosphatase 5: impairment in Alzheimer's disease</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>3</issue><fpage>1790</fpage><lpage>1796</lpage><pub-id pub-id-type="pmid">15546861</pub-id></citation></ref><ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Leight</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unique Alzheimer's
disease paired helical filament specific epitopes involve double
phosphorylation at specific sites</article-title><source><italic>Biochemistry</italic></source><year>1997</year><volume>36</volume><issue>26</issue><fpage>8114</fpage><lpage>8124</lpage><pub-id pub-id-type="pmid">9201960</pub-id></citation></ref><ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Crowther</surname><given-names>R</given-names></name><etal/></person-group><article-title>Characterization of
mAb AP422, a novel phosphorylation-dependentmonoclonal
antibody against tau protein</article-title><source><italic>FEBS Letters</italic></source><year>1996</year><volume>384</volume><issue>1</issue><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8797796</pub-id></citation></ref><ref id="B92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bussiere</surname><given-names>T</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Mailliot</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phosphorylated serine422
on tau proteins is a pathological epitope found in
several diseases with neurofibrillary degeneration</article-title><source><italic>Acta Neuropathologica (Berl)</italic></source><year>1999</year><volume>97</volume><issue>3</issue><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">10090668</pub-id></citation></ref><ref id="B93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Thangavel</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Phosphorylation of
tau by fyn: implications for Alzheimer's disease</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2004</year><volume>24</volume><issue>9</issue><fpage>2304</fpage><lpage>2312</lpage><pub-id pub-id-type="pmid">14999081</pub-id></citation></ref><ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>R</given-names></name><name><surname>Scales</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Rapid tyrosine phosphorylation
of neuronal proteins including tau and focal adhesion
kinase in response to amyloid-&#x003b2; peptide exposure: involvement
of Src family protein kinases</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2002</year><volume>22</volume><issue>1</issue><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11756483</pub-id></citation></ref><ref id="B95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derkinderen</surname><given-names>P</given-names></name><name><surname>Scales</surname><given-names>TM</given-names></name><name><surname>Hanger</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Tyrosine 394
is phosphorylated in Alzheimer's paired helical filament tau
and in fetal tau with c-Abl as the candidate tyrosine kinase</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2005</year><volume>25</volume><issue>28</issue><fpage>6584</fpage><lpage>6593</lpage><pub-id pub-id-type="pmid">16014719</pub-id></citation></ref><ref id="B96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>M</given-names></name><name><surname>Dawson</surname><given-names>HN</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name><etal/></person-group><article-title>Tau is essential to beta -amyloid-induced neurotoxicity</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2002</year><volume>99</volume><issue>9</issue><fpage>6364</fpage><lpage>6369</lpage><pub-id pub-id-type="pmid">11959919</pub-id></citation></ref><ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brich</surname><given-names>J</given-names></name><name><surname>Shie</surname><given-names>FS</given-names></name><name><surname>Howell</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Genetic modulation of tau
phosphorylation in the mouse</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2003</year><volume>23</volume><issue>1</issue><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">12514215</pub-id></citation></ref><ref id="B98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Neurodegenerative
tauopathies</article-title><source><italic>Annual Review of Neuroscience</italic></source><year>2001</year><volume>24</volume><fpage>1121</fpage><lpage>1159</lpage></citation></ref><ref id="B99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bancher</surname><given-names>C</given-names></name><name><surname>Brunner</surname><given-names>C</given-names></name><name><surname>Lassman</surname><given-names>H</given-names></name><etal/></person-group><article-title>Accumulation of
abnormally phosphorylated tau precedes the formation of
neurofibrillary tangles in Alzheimer's disease</article-title><source><italic>Brain Research</italic></source><year>1989</year><volume>477</volume><issue>1-2</issue><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">2495152</pub-id></citation></ref><ref id="B100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bancher</surname><given-names>C</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Abnormal
phosphorylation of tau precedes ubiquitination in neurofibrillary
pathology of Alzheimer disease</article-title><source><italic>Brain Research</italic></source><year>1991</year><volume>539</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1849776</pub-id></citation></ref><ref id="B101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>E</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Mandelkow</surname><given-names>E-M</given-names></name></person-group><article-title>A sequence of cytoskeletal
changes related to the formation of neurofibrillary tangles
and neuropil threads</article-title><source><italic>Acta Neuropathologica</italic></source><year>1994</year><volume>87</volume><fpage>544</fpage><lpage>567</lpage></citation></ref><ref id="B102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Kabat</surname><given-names>J</given-names></name><name><surname>Novak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Maximal inhibition of
tau binding to microtubules requires the phosphorylation
of tau at both Thr 231 and Ser 262</article-title><source><italic>Neurobiology of Aging</italic></source><year>1998</year><volume>19S</volume><fpage>S124</fpage><lpage>S524</lpage></citation></ref><ref id="B103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Biernat</surname><given-names>J</given-names></name><name><surname>von Bergen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phosphorylation
that detaches tau protein from microtubules (Ser262, Ser214)
also protects it against aggregation into Alzheimer paired helical
filaments</article-title><source><italic>Biochemistry</italic></source><year>1999</year><volume>38</volume><issue>12</issue><fpage>3549</fpage><lpage>3558</lpage><pub-id pub-id-type="pmid">10090741</pub-id></citation></ref><ref id="B104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abraha</surname><given-names>A</given-names></name><name><surname>Ghoshal</surname><given-names>N</given-names></name><name><surname>Gamblin</surname><given-names>TC</given-names></name><etal/></person-group><article-title>C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease</article-title><source><italic>Journal of Cell Science</italic></source><year>2000</year><volume>113</volume><issue>pt 21</issue><fpage>3737</fpage><lpage>3745</lpage><pub-id pub-id-type="pmid">11034902</pub-id></citation></ref><ref id="B105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>C</given-names></name><name><surname>Stieler</surname><given-names>J</given-names></name><name><surname>Arendt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pseudophosphorylation of tau protein alters its ability for self-aggregation</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2004</year><volume>88</volume><issue>6</issue><fpage>1509</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">15009652</pub-id></citation></ref><ref id="B106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Hoerndli</surname><given-names>F</given-names></name><name><surname>Baechi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Beta-amyloid induces
paired helical filament-like tau filaments in tissue culture</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>41</issue><fpage>40162</fpage><lpage>40168</lpage><pub-id pub-id-type="pmid">12893817</pub-id></citation></ref><ref id="B107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>A</given-names></name><name><surname>Oguchi</surname><given-names>K</given-names></name><name><surname>Okabe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Altered microtubule organization
in small-calibre axons of mice lacking tau protein</article-title><source><italic>Nature</italic></source><year>1994</year><volume>369</volume><issue>6480</issue><fpage>488</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">8202139</pub-id></citation></ref><ref id="B108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alonso Adel</surname><given-names>C</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Barra</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Abnormal
phosphorylation of tau and themechanism of Alzheimer
neurofibrillary degeneration: sequestration of microtubuleassociated
proteins 1 and 2 and the disassembly of microtubules
by the abnormal tau</article-title><source><italic>Proceedings of the National
Academy of Sciences of the United States of America</italic></source><year>1997</year><volume>94</volume><issue>1</issue><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">8990203</pub-id></citation></ref><ref id="B109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Borrell</surname><given-names>J</given-names></name><name><surname>Guaza</surname><given-names>C</given-names></name><etal/></person-group><article-title>Spatial learning deficit
in transgenic mice that conditionally over-express GSK-3beta
in the brain but do not form tau filaments</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2002</year><volume>83</volume><issue>6</issue><fpage>1529</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">12472906</pub-id></citation></ref><ref id="B110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Kenyon</surname><given-names>TK</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Transgenic animal
models of tauopathies</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2005</year><volume>1739</volume><issue>2-3</issue><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">15615643</pub-id></citation></ref><ref id="B111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Head</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Common structure of
soluble amyloid oligomers implies common mechanism of
pathogenesis</article-title><source><italic>Science</italic></source><year>2003</year><volume>300</volume><issue>5618</issue><fpage>486</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">12702875</pub-id></citation></ref><ref id="B112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanbe</surname><given-names>A</given-names></name><name><surname>Osinska</surname><given-names>H</given-names></name><name><surname>Villa</surname><given-names>C</given-names></name><etal/></person-group><article-title>Reversal of amyloidinduced
heart disease in desmin-related cardiomyopathy</article-title><source><italic>Proceedings of the National Academy of Sciences of the United
States of America</italic></source><year>2005</year><volume>102</volume><issue>38</issue><fpage>13592</fpage><lpage>13597</lpage><pub-id pub-id-type="pmid">16155124</pub-id></citation></ref><ref id="B113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>LF</given-names></name><name><surname>Schachter</surname><given-names>JB</given-names></name><name><surname>Seymour</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Tau protein phosphorylation
as a therapeutic target in Alzheimer's disease</article-title><source><italic>Current Topics in Medicinal Chemistry.</italic></source><year>2002</year><volume>2</volume><issue>4</issue><fpage>395</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">11966463</pub-id></citation></ref><ref id="B114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Role of serine/threonine protein phosphatase
in Alzheimer's disease</article-title><source><italic>Neurosignals</italic></source><year>2002</year><volume>11</volume><issue>5</issue><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">12566927</pub-id></citation></ref><ref id="B115"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>GV</given-names></name><name><surname>Stoothoff</surname><given-names>WH</given-names></name></person-group><article-title>Tau phosphorylation in neuronal
cell function and dysfunction</article-title><source><italic>Journal of Cell Science</italic></source><year>2004</year><volume>117</volume><issue>pt 24</issue><fpage>5721</fpage><lpage>5729</lpage><pub-id pub-id-type="pmid">15537830</pub-id></citation></ref><ref id="B116"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Qi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Protein phosphatase 2A is
the major enzyme in brain that dephosphorylates tau protein
phosphorylated by proline-directed protein kinases or
cyclic AMP-dependent protein kinase</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1995</year><volume>65</volume><issue>6</issue><fpage>2804</fpage><lpage>2807</lpage><pub-id pub-id-type="pmid">7595582</pub-id></citation></ref><ref id="B117"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontag</surname><given-names>E</given-names></name><name><surname>Nunbhakdi-Craig</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><etal/></person-group><article-title>Regulation of
the phosphorylation state and microtubule-binding activity
of Tau by protein phosphatase 2A</article-title><source><italic>Neuron</italic></source><year>1996</year><volume>17</volume><issue>6</issue><fpage>1201</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">8982166</pub-id></citation></ref><ref id="B118"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontag </surname><given-names>E</given-names></name><name><surname>Nunbhakdi-Craig</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular interactions
among protein phosphatase 2A, tau, and microtubules.
Implications for the regulation of tau phosphorylation
and the development of tauopathies</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1999</year><volume>274</volume><issue>36</issue><fpage>25490</fpage><lpage>25498</lpage><pub-id pub-id-type="pmid">10464280</pub-id></citation></ref><ref id="B119"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennecib</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Role of protein
phosphatase-2A and -1 in the regulation of GSK-3, cdk5
and cdc2 and the phosphorylation of tau in rat forebrain</article-title><source><italic>FEBS Letters</italic></source><year>2000</year><volume>485</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">11086171</pub-id></citation></ref><ref id="B120"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kins</surname><given-names>S</given-names></name><name><surname>Crameri</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Reduced protein phosphatase
2A activity induces hyperphosphorylation and altered
compartmentalization of tau in transgenic mice</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>41</issue><fpage>38193</fpage><lpage>38200</lpage><pub-id pub-id-type="pmid">11473109</pub-id></citation></ref><ref id="B121"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Truncation and activation
of calcineurin A by calpain l in Alzheimer disease brain</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>45</issue><fpage>37755</fpage><lpage>37762</lpage><pub-id pub-id-type="pmid">16150694</pub-id></citation></ref><ref id="B122"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Potentiation of
GSK-3-catalyzed Alzheimer-like phosphorylation of human
tau by cdk5</article-title><source><italic>Molecular and Cellular Biochemistry</italic></source><year>1997</year><volume>167</volume><issue>1-2</issue><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">9059986</pub-id></citation></ref><ref id="B123"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J-Z</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><etal/></person-group><article-title>&#x003c4; is phosphorylated by GSK- 3 at several sites found in Alzheimer disease and its biological
activity markedly inhibited only after it is prephosphorylated
by A-kinase</article-title><source><italic>FEBS Letters</italic></source><year>1998</year><volume>436</volume><issue>1</issue><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9771888</pub-id></citation></ref><ref id="B124"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Tau becomes a more favorable
substrate for GSK-3 when it is prephosphorylated
by PKA in rat brain</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2004</year><volume>279</volume><issue>48</issue><fpage>50078</fpage><lpage>50088</lpage><pub-id pub-id-type="pmid">15375165</pub-id></citation></ref><ref id="B125"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name></person-group><article-title>Glycogen synthase kinase 3beta phosphorylates
tau at both primed and unprimed sites. Differential
impact on microtubule binding</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>1</issue><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">12409305</pub-id></citation></ref><ref id="B126"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name></person-group><article-title>Primed phosphorylation of tau at
Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a
critical role in regulating tau's ability to bind and stabilize microtubules</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2004</year><volume>88</volume><issue>2</issue><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">14690523</pub-id></citation></ref><ref id="B127"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bilateral injection of isoproterenol
into hippocampus induces Alzheimer-like hyperphosphorylation
of tau and spatial memory deficit in rat</article-title><source><italic>FEBS Letters</italic></source><year>2005</year><volume>579</volume><issue>1</issue><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">15620722</pub-id></citation></ref><ref id="B128"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>AH</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Overactivation of glycogen
synthase kinase-3 by inhibition of phosphoinositol-3 kinase
and protein kinase C leads to hyperphosphorylation of tau
and impairment of spatial memory</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2003</year><volume>87</volume><issue>6</issue><fpage>1333</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">14713290</pub-id></citation></ref><ref id="B129"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baki</surname><given-names>L</given-names></name><name><surname>Shioi </surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>P</given-names></name><etal/></person-group><article-title>PS1 activates PI3K thus inhibiting
GSK-3 activity and tau overphosphorylation: effects of FAD
mutations</article-title><source><italic>The EMBO Journal</italic></source><year>2004</year><volume>23</volume><issue>13</issue><fpage>2586</fpage><lpage>2596</lpage><pub-id pub-id-type="pmid">15192701</pub-id></citation></ref><ref id="B130"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Activation of glycogen synthase
kinase-3 induces Alzheimer-like tau hyperphosphorylation
in rat hippocampus slices in culture</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2006</year><volume>113</volume><issue>1</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">15959856</pub-id></citation></ref><ref id="B131"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>YQ</given-names></name><name><surname>Xu</surname><given-names>GG</given-names></name><name><surname>Duan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of melatonin on
wortmannin-induced tau hyperphosphorylation</article-title><source><italic>Acta Pharmacologica Sinica</italic></source><year>2005</year><volume>26</volume><issue>5</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">15842767</pub-id></citation></ref><ref id="B132"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>GN</given-names></name><name><surname>Zukerberg</surname><given-names>L</given-names></name><name><surname>Nikolic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Conversion of p35
to p25 deregulates Cdk5 activity and promotes neurodegeneration</article-title><source><italic>Nature</italic></source><year>1999</year><volume>402</volume><issue>6762</issue><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">10604467</pub-id></citation></ref><ref id="B133"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>BC</given-names></name><name><surname>Lubec</surname><given-names>G</given-names></name></person-group><article-title>p25 protein in neurodegeneration</article-title><source><italic>Nature</italic></source><year>2001</year><volume>411</volume><issue>6839</issue><fpage>763</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">11459045</pub-id></citation></ref><ref id="B134"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains</article-title><source><italic>FEBS Letters</italic></source><year>2001</year><volume>489</volume><issue>1</issue><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11231011</pub-id></citation></ref><ref id="B135"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>KC</given-names></name><name><surname>Rosales</surname><given-names>JL</given-names></name><name><surname>Barboza</surname><given-names>M</given-names></name><etal/></person-group><article-title>Controversies over p25 in Alzheimer's disease</article-title><source><italic>Journal of Alzheimer's Disease</italic></source><year>2002</year><volume>4</volume><issue>2</issue><fpage>123</fpage><lpage>126</lpage></citation></ref><ref id="B136"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Brain levels of CDK5 activator
p25 are not increased in Alzheimer's or other neurodegenerative
diseases with neurofibrillary tangles</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2003</year><volume>86</volume><issue>3</issue><fpage>572</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">12859671</pub-id></citation></ref><ref id="B137"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><etal/></person-group><article-title>The regulation of phosphorylation
of tau in SY5Y neuroblastoma cells: the role of
protein phosphatases</article-title><source><italic>FEBS Letters</italic></source><year>1998</year><volume>426</volume><issue>2</issue><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">9599018</pub-id></citation></ref><ref id="B138"><label>138</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennecib</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Inhibition
of PP-2A upregulates CaMKII in rat forebrain and induces
hyperphosphorylation of tau at Ser 262/356</article-title><source><italic>FEBS Letters</italic></source><year>2001</year><volume>490</volume><issue>1-2</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11172803</pub-id></citation></ref><ref id="B139"><label>139</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>J-J</given-names></name><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>An</surname><given-names>W</given-names></name><etal/></person-group><article-title>Okadaic-acid-induced inhibition
of protein phosphatase 2A produces activation of
mitogen-activated protein kinases ERK1/2, MEK1/2, and p70
S6, similar to that in Alzheimer's disease</article-title><source><italic>The American Journal of Pathology</italic></source><year>2003</year><volume>163</volume><issue>3</issue><fpage>845</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">12937126</pub-id></citation></ref><ref id="B140"><label>140</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kins</surname><given-names>S</given-names></name><name><surname>Kurosinski</surname><given-names>P</given-names></name><name><surname>Nitsch</surname><given-names>RM</given-names></name><name><surname>Gotz</surname><given-names>J</given-names></name></person-group><article-title>Activation of the
ERK and JNK signaling pathways caused by neuron-specific
inhibition of PP2A in transgenic mice</article-title><source><italic>The American Journal of Pathology</italic></source><year>2003</year><volume>163</volume><issue>3</issue><fpage>833</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">12937125</pub-id></citation></ref><ref id="B141"><label>141</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>W-L</given-names></name><name><surname>Cowburn</surname><given-names>RF</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary
pathology in Alzheimer's disease</article-title><source><italic>The American Journal of Pathology</italic></source><year>2003</year><volume>163</volume><issue>2</issue><fpage>591</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">12875979</pub-id></citation></ref><ref id="B142"><label>142</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanimukai</surname><given-names>H</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name></person-group><article-title>Up-regulation of inhibitors
of protein phosphatase-2A in Alzheimer's disease</article-title><source><italic>The American Journal of Pathology</italic></source><year>2005</year><volume>166</volume><issue>6</issue><fpage>1761</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">15920161</pub-id></citation></ref><ref id="B143"><label>143</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>CS</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name><name><surname>Cole</surname><given-names>RN</given-names></name><etal/></person-group><article-title>The microtubuleassociated
protein tau is extensively modified with O-linked
N-acetylglucosamine</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1996</year><volume>271</volume><issue>46</issue><fpage>28741</fpage><lpage>28744</lpage><pub-id pub-id-type="pmid">8910513</pub-id></citation></ref><ref id="B144"><label>144</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>T</given-names></name><name><surname>Ferreira</surname><given-names>S</given-names></name><name><surname>Dupont-Wallois</surname><given-names>L</given-names></name><etal/></person-group><article-title>Evidence of a
balance between phosphorylation and O-GlcNAc glycosylation
of Tau proteins&#x02014;a role in nuclear localization</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2003</year><volume>1619</volume><issue>2</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12527113</pub-id></citation></ref><ref id="B145"><label>145</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>O-GlcNAcylation
regulates phosphorylation of tau: a mechanism involved in
Alzheimer's disease</article-title><source><italic>Proceedings of the National Academy of
Sciences of the United States of America</italic></source><year>2004</year><volume>101</volume><issue>29</issue><fpage>10804</fpage><lpage>10809</lpage><pub-id pub-id-type="pmid">15249677</pub-id></citation></ref><ref id="B146"><label>146</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comer</surname><given-names>FI</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><article-title>O-Glycosylation of nuclear and cytosolic
proteins. Dynamic interplay between O-GlcNAc and Ophosphate</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>275</volume><issue>38</issue><fpage>29179</fpage><lpage>29182</lpage><pub-id pub-id-type="pmid">10924527</pub-id></citation></ref><ref id="B147"><label>147</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>LA</given-names></name><name><surname>Moya</surname><given-names>KL</given-names></name><name><surname>Breen</surname><given-names>KC</given-names></name></person-group><article-title>The potential role of
tau protein O-glycosylation in Alzheimer's disease</article-title><source><italic>Journal of Alzheimer's Disease</italic></source><year>2004</year><volume>6</volume><issue>5</issue><fpage>489</fpage><lpage>495</lpage></citation></ref><ref id="B148"><label>148</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C-X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation</article-title><source><italic>Journal of Alzheimer's Disease</italic></source><year>2006</year><comment>in press.</comment></citation></ref><ref id="B149"><label>149</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahishi</surname><given-names>M</given-names></name><name><surname>Tsumioka</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><etal/></person-group><article-title>Glycosylation
of microtubule-associated protein tau in Alzheimer's disease brain</article-title><source><italic>Acta Neuropathologica (Berl)</italic></source><year>1999</year><volume>97</volume><issue>6</issue><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">10378383</pub-id></citation></ref><ref id="B150"><label>150</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Role of glycosylation
in hyperphosphorylation of tau in Alzheimer's disease</article-title><source><italic>FEBS Letters</italic></source><year>2002</year><volume>512</volume><issue>1&#x02013;3</issue><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11852060</pub-id></citation></ref><ref id="B151"><label>151</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zaidi</surname><given-names>T</given-names></name><name><surname>Grandke-Iqbal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Aberrant glycosylation
modulates phosphorylation of tau by protein kinase A and
dephosphorylation of tau by protein phosphatase 2A and 5</article-title><source><italic>Neuroscience</italic></source><year>2002</year><volume>115</volume><issue>3</issue><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">12435421</pub-id></citation></ref><ref id="B152"><label>152</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Involvement of aberrant
glycosylation in phosphorylation of tau by cdk5 and GSK-3&#x003b2;</article-title><source><italic>FEBS Letters</italic></source><year>2002</year><volume>530</volume><issue>1&#x02013;3</issue><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">12387894</pub-id></citation></ref><ref id="B153"><label>153</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Poritis</surname><given-names>N</given-names></name></person-group><article-title>Memantine in severe dementia: results
of the 9M-Best Study (Benefit and efficacy in severely demented
patients during treatment with memantine)</article-title><source><italic>International Journal of Geriatric Psychiatry</italic></source><year>1999</year><volume>14</volume><issue>2</issue><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">10885864</pub-id></citation></ref><ref id="B154"><label>154</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>A</given-names></name><name><surname>Stoffler</surname><given-names>A</given-names></name></person-group><article-title>Memantine in moderateto severe Alzheimer's disease</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2003</year><volume>348</volume><issue>14</issue><fpage>1333</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">12672860</pub-id></citation></ref><ref id="B155"><label>155</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Haque</surname><given-names>N</given-names></name><etal/></person-group><article-title>Memantine inhibits and
reverses the Alzheimer type abnormal hyperphosphorylation
of tau and associated neurodegeneration</article-title><source><italic>FEBS Letters</italic></source><year>2004</year><volume>566</volume><issue>1&#x02013;3</issue><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">15147906</pub-id></citation></ref><ref id="B156"><label>156</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SP</given-names></name><name><surname>Deng</surname><given-names>YQ</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Melatonin protects SHSY5Y
neuroblastoma cells from calyculin A-induced neurofilament
impairment and neurotoxicity</article-title><source><italic>Journal of Pineal Research</italic></source><year>2004</year><volume>36</volume><issue>3</issue><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">15009509</pub-id></citation></ref><ref id="B157"><label>157</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XC</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Effect of melatonin on calyculin
A-induced tau hyperphosphorylation</article-title><source><italic>European Journal of Pharmacology</italic></source><year>2005</year><volume>510</volume><issue>1-2</issue><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15740721</pub-id></citation></ref><ref id="B158"><label>158</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>LQ</given-names></name><name><surname>Wang</surname><given-names>SH</given-names></name><name><surname>Ling</surname><given-names>ZQ</given-names></name><etal/></person-group><article-title>Effect of inhibiting
melatonin biosynthesis on spatial memory retention
and tau phosphorylation in rat</article-title><source><italic>Journal of Pineal Research</italic></source><year>2004</year><volume>37</volume><issue>2</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">15298664</pub-id></citation></ref><ref id="B159"><label>159</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>DL</given-names></name><name><surname>Ling</surname><given-names>ZQ</given-names></name><name><surname>Cao</surname><given-names>FY</given-names></name><etal/></person-group><article-title>Melatonin attenuates
isoproterenol-induced protein kinase A overactivation and
tau hyperphosphorylation in rat brain</article-title><source><italic>Journal of Pineal Research</italic></source><year>2004</year><volume>37</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15230863</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="F1" position="float"><label>Figure 1</label><caption><p>Proposed mechanism of neurofibrillary degeneration. MAPs, microtubule-associated proteins; MTs, microtubules; PHFs, paired helical filaments; NFTs, neurofibrillary tangles.</p></caption><graphic xlink:href="JBB2006-31825.001"/></fig></sec></back></article>





